The release of T/CIAA 008—2026, the revised group standard for antimicrobial sanitary pads, pantyliners and period pants, marks a pivotal shift in China's hygiene product industry. Following the recent implementation of the national standard GB 15979-2024, this update introduces a 'long-lasting antimicrobial (bacteriostatic)' requirement that mandates products to maintain efficacy after simulated use. For upstream suppliers of nonwoven fabrics and functional additives, this signals a systemic elevation of technical barriers.
Industry Logic Behind the Revision
The standard, administered by the Zhongguancun Huizhi Antimicrobial New Material Industry Technology Innovation Alliance, was drafted by Henan Shulai, Guangdong Institute of Microbiology, SGS, and Jinda Nano Technology, among others. It replaces the 2020 version, aligning definitions, requirements, and test methods with GB 15979-2024. The most notable addition is the definition of 'long-lasting antimicrobial' efficacy, which involves applying bovine serum albumin to the skin-contact layer and incubating at 36±1°C for at least 8 hours before evaluating antimicrobial activity. This simulates real-world conditions of body temperature and secretions, bridging the gap between lab results and actual usage.
This change directly addresses the long-standing issue of overclaimed but under-verified antimicrobial performance. Previously, products only needed to meet inhibition rates at the factory gate. Now, they must demonstrate sustained effectiveness, pushing manufacturers to develop antimicrobial agents with better slow-release properties or resistance to bodily fluids. For suppliers of masterbatches, nano-silver, and chitosan, creating systems that pass the 8-hour simulation will be the next battleground.
Ripple Effects Across the Supply Chain
The stricter requirements impact materials such as nonwoven top sheets, absorbent cores, and leak-proof films. The top sheet, in direct contact with skin, can no longer rely on simple surface treatment; it must ensure continuous release of antimicrobial agents in a fluid-rich environment. This influences the choice of nonwoven technology—spunbond, thermal bond, or spunlace—with thermal bond offering higher loft and faster liquid penetration, potentially aiding uniform distribution, but requiring validation of residual activity after the 8-hour test.
For manufacturers, formulation and process validation costs will rise. The long-lasting efficacy test involves biological reagents and longer testing cycles, making third-party certification more expensive. This raises entry barriers for smaller brands but also creates differentiation opportunities. Early adopters can market 'long-lasting protection' claims, building consumer trust in an era of heightened safety awareness.